Skip to main content
SpringerLink
Log in

No effect of bezafibrate in patients with CPTII and VLCAD deficiencies

  • Letter to the Editors
  • Published:
Journal of Inherited Metabolic Disease

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Astrand PO, Rodahl K, Dahl HA, Stromme SB (2003) Textbook of work physiology. Physiological bases of exercise. Human Kinetics, Champaign

    Google Scholar 

  • Bonnefont JP, Bastin J, Behin A, Djouadi F (2009) Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 360(8):838–840

    Article  CAS  PubMed  Google Scholar 

  • Djouadi F, Bastin J (2008) PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 31(2):217–225

    Article  CAS  PubMed  Google Scholar 

  • Orngreen MC, Olsen DB, Vissing J (2002) Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology 59(7):1046–1051

    Article  CAS  PubMed  Google Scholar 

  • Orngreen MC, Ejstrup R, Vissing J (2003) Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 61(4):559–561

    Article  PubMed  Google Scholar 

  • Orngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforet P (2014) Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology 82(7):607–613

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuromuscular Clinic and Research Unit, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

    Mette Cathrine Ørngreen & John Vissing

  2. Centre de Référence de Pathologie Neuromusculaire Paris-Est, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France

    Pascal Laforét

Authors
  1. Mette Cathrine Ørngreen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Vissing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pascal Laforét
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mette Cathrine Ørngreen.

Additional information

Communicated by: Verena Peters

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ørngreen, M.C., Vissing, J. & Laforét, P. No effect of bezafibrate in patients with CPTII and VLCAD deficiencies. J Inherit Metab Dis 38, 373–374 (2015). https://doi.org/10.1007/s10545-014-9779-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-014-9779-3

Keywords

Search

Navigation